The widespread adoption of weight-loss drugs is reducing demand for products like wine bottles and beer cans. This introduces a significant, unforeseen secular risk to packaging companies, a sector traditionally considered a safe bet by credit investors who often focus only on coupon payments and credit ratings.

A world-famous chef claims the mid-tier restaurant business is "over." Patrons on drugs like Ozempic eat less, and younger generations drink less alcohol, drastically reducing average check sizes. This makes the economics of a $75-per-person establishment unsustainable, leaving only high-end and fast-casual options viable.

A surprising driver of Fruitist's success is the Ozempic effect. GLP-1 drug users consume more fruit but are averse to "surprises" in taste or texture. This creates demand for branded, highly consistent produce, allowing companies like Fruitist to command a premium price from this growing consumer segment.

The widespread adoption of GLP-1 drugs for obesity, projected to reach 25 million U.S. users, will significantly reduce food, soda, and alcohol consumption. This presents a material, long-term revenue threat to consumer-facing industries like fast food, snack companies, and even casinos, forcing investors in those sectors to adjust their models.

The consumer demand for protein, partly fueled by GLP-1 drug users, is causing dairy producers to ramp up whey protein production. Since cheese is a byproduct of whey, massive new cheese plants are being built, which will flood the market with cheap, soft cheeses while aged varieties become scarce.

The widespread adoption of GLP-1 therapies is projected to decrease total U.S. calorie consumption by 1.6% by 2035. This second-order effect will create significant disruption and headwinds for industries reliant on consumer food purchasing, including the CPG, retail, and restaurant sectors.

Consumer understanding of protein's importance has shifted from a niche bodybuilding concept to a mainstream health focus. This creates a durable, secular trend supporting the entire category, potentially insulating companies like BellRing from short-term fads and even aligning with new trends like GLP-1 drug usage.

The stock's plunge from over $80 to $17 isn't linked to a specific catastrophic event. It's likely the unwinding of a speculative run-up where valuation outpaced fundamentals. This overcorrection, driven by market psychology rather than a broken business, can create significant opportunities for value investors.

While politicians may attack brands like Dunkin' Donuts, the real threat to the fast-food industry comes from GLP-1 drugs like Ozempic. These drugs could fundamentally alter consumer appetite and demand, representing a more direct and powerful disruptive force than any regulation or PR battle.